High-Flying Biotech Valuations Are Falling – And Maybe That’s A Good Thing
Big Pharma Focused On Science, Not Prior Funding
Venture capitalists speaking at Biocom’s Global Life Science Partnering Conference looked forward to a return to rational valuations that could enable better returns for investors and pharma buyers.
